Hennes primary project is to create a new molecular prognostic score for Follicular Lymphoma. He thinks that through a multidisciplinary approach of genomic, proteomic, transcriptomic, immunological analysis and machine learning will allow us to better understand the disease and further the treatment of cancer. He is interested in the development of liquid biopsies via technologies like 3D-printing, Recombinase Polymerase Amplification and Methylscape. His clinical background allows him to combine practical clinical practice with cutting edge technology to further the advancement of healthcare.

​Hennes has completed two years of the MD at UQ from 2017-2018. He received a UQGSS PhD scholarship and started his PhD in 2019 with the Gandhi group at MRI-UQ and Trau Group at AIBN. He plans to intercalate his PhD with the final two years of the MD from 2020-2022. Hennes has previously gained First-Class Honours with the Trau group in 2016. 

Key Publications

  1. Isothermal Point Mutation Detection: Toward a First-Pass Screening Strategy for Multidrug-Resistant Tuberculosis. Analytical Chemistry. 2017;89(17):9017-22. Ng BYC, Wee EJH, Woods K, Anderson W, Antaw F, Tsang HZH, et al.